Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?
暂无分享,去创建一个
[1] S. Rosenberg,et al. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma , 2016, Clinical Cancer Research.
[2] F. Hodi,et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma , 2016, Journal of Immunotherapy for Cancer.
[3] J. Wolchok,et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.
[4] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[5] J. Wargo,et al. Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma , 2014, Oncoimmunology.
[6] S. Rosenberg,et al. Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.
[7] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[8] R. Sullivan,et al. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.
[9] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Flaherty,et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.
[11] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.